**Supplementary Table 1. Treatment regimens based on** **EBUS-TBNA and LB results**

|  |  |
| --- | --- |
| **Treatment regimen** | **Number of patients treated (%)** |
| Afatinib  | 2 (4.5%) |
| Atezolizumab  | 1 (2.3%) |
| Carboplatin/paclitaxel/atezolizumab/bevacizumab  | 1 (2.3%) |
| Carboplatin/gemcitabine  | 1 (2.3%) |
| Carboplatin/paclitaxel ± XRT | 2 (4.6%) |
| Carboplatin/paclitaxel/pembrolizumab | 1 (2.3%) |
| Carboplatin/paclitaxel-protein bound ± pembrolizumab  | 4 (9.1%) |
| Carboplatin/fluorouracil/pembrolizumab | 1 (2.3%) |
| Carboplatin/pemetrexed ± pembrolizumab | 12 (27.2%) |
| Cisplatin/docetaxel Cisplatin/etoposide/durvalumabCisplatin/gemcitabineCisplatin/pemetrexed Crizotinib | 1 (2.3%)1 (2.3%)1 (2.3%)3 (6.8%)1 (2.3%) |
| Durvalumab | 1 (2.3%) |
| Gefitinib | 1 (2.3%) |
| Gemcitabine | 1 (2.3%) |
| Larotrectinib | 1 (2.3%) |
| Nivolumab | 2 (4.5%) |
| Osimertinib | 4 (9.1%) |
| Pembrolizumab | 1 (2.3%) |

EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; LB, liquid biopsy; XRT, radiation therapy